Clinical data
Other namesCIN-102; deuterated domperidone; domperidone deuterated
  • 3-[3-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propyl]-4,5,6,7-tetradeuterio-1H-benzimidazol-2-one
CAS Number
  • 2121525-08-2
PubChem CID
Chemical and physical data
Molar mass429.94 g·mol−1
3D model (JSmol)
  • [2H]C1=C(C(=C2C(=C1[2H])NC(=O)N2CCCN3CCC(CC3)N4C5=C(C=C(C=C5)Cl)NC4=O)[2H])[2H]
  • InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)/i1D,2D,4D,5D

Deudomperidone (developmental code name CIN-102; also known as deuterated domperidone) is a dopamine antagonist medication which is under development in the United States for the treatment of gastroparesis.[1][2][3] It acts as a selective dopamine D2 and D3 receptor antagonist and has peripheral selectivity.[2][3] Deudomperidone is a deuterated form of domperidone, and it is suggested that deudomperidone may have improved efficacy, tolerability, and pharmacokinetics compared to domperidone.[2][3] As of August 2021, deudomperidone is in phase 2 clinical trials for the treatment of gastroparesis.[1]


  1. ^ a b "Deudomperidone - CinRx Pharma - AdisInsight".
  2. ^ a b c Heckroth M, Luckett RT, Moser C, Parajuli D, Abell TL (April 2021). "Nausea and Vomiting in 2021: A Comprehensive Update". J Clin Gastroenterol. 55 (4): 279–299. doi:10.1097/MCG.0000000000001485. PMC 7933092. PMID 33471485.
  3. ^ a b c Wo, John M.; McCallum, Richard W.; Gonzalez, Zorisadday (2021). "Antiemetic therapy for gastroparesis". Gastroparesis. Elsevier. pp. 341–359. doi:10.1016/B978-0-12-818586-5.00025-9. ISBN 9780128185865. S2CID 225132800.